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BIMChronic myeloid leukemia (CML) is a myeloproliferative disease caused by the constitutive tyrosine kinase
(TK) activity of the BCR-ABL fusion protein. However, the phenotype of leukemic stem cells (LSC) is sustained
by β catenin rather than by the BCR-ABL TK. β catenin activity in CML is contingent upon its stabilization pro-
ceeding from the BCR-ABL-induced phosphorylation at critical residues for interaction with the Adenomatous
polyposis coli (APC)/Axin/glycogen synthase kinase 3 (GSK3) destruction complex or GSK3 inactivating mu-
tations. Here we studied the impact of β catenin antagonist Chibby (CBY) on β catenin signaling in
BCR-ABL1+ cells. CBY is a small conserved protein which interacts with β catenin and impairs β catenin-
mediated transcriptional activation through two distinct molecular mechanisms: 1) competition with T cell
factor (TCF) or lymphoid enhancer factor (LEF) for β catenin binding; and 2) nuclear export of β catenin
via interaction with 14-3-3. We found that its enforced expression in K562 cell line promoted β catenin cy-
toplasmic translocation resulting in inhibition of target gene transcription. Moreover, cytoplasmic accumula-
tion of β catenin activated the endoplasmic reticulum (ER) stress-associated pathway known as unfolded
protein response (UPR). CBY-driven cytoplasmic accumulation of β catenin is also a component of BCR-
ABL1+ cell response to the TK inhibitor Imatinib (IM). It evoked the UPR activation leading to the induction
of BCL2-interacting mediator of cell death (BIM) by UPR sensors. BIM, in turn, contributed to the execution
phase of apoptosis in the activation of ER resident caspase 12 and mobilization of Ca2+ stores.
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CML is a myeloproliferative disease originated from a pluripotent
hematopoietic cell, the LSC, harboring the t [9,22] reciprocal transloca-
tion which generates the BCR-ABL1 rearranged gene. This single ge-
netic lesion drives the clonal expansion of leukemic hematopoiesis
through the constitutively activated TK of its protein [1]. Accordingly,
the majority of CML patients undergo complete hematologic remis-
sion in response to the TK inhibitor IM [2]. However, BCR-ABL1+
LSC are neither dependent on BCR-ABL TK for proliferation and surviv-
al nor killed by IM and second generation inhibitors Nilotinib and
Dasatinib, hence providing a sanctuary for the disease relapse upon
drug withdrawal and a putative source of drug-resistance [3].
β catenin is a central component of BCR-ABL1+ LSC self-renewal
[4,5]. Moreover, it may have a role in the reprogramming of commit-
ted granulocyte/macrophage progenitors into LSC at the blast crisis
(BC) onset [6]. β catenin activation in CML cells is contingent upon
the BCR-ABL-mediated phosphorylation, which promotes stabiliza-
tion of β catenin by blocking its binding to APC/Axin/GSK3 destruc-
tion complex, or GSK3β missplicing, due to in-frame splice deletion
of its kinase domain. Subsequently, β catenin translocates into the
nucleus to form a transcription complex with TCF/LEF factors andcense. 
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D1 [7,8]. Indeed, β catenin subcellular location is crucial for its sig-
naling activation. Accordingly it is tightly regulated by multiple
mechanisms in association with carrier proteins such as 14-3-3,
importin-α and chromosomal region maintenance 1 (CRM1)/
exportin 1 [9].
CBY is a 14.5 kDa protein highly conserved throughout evolution.
It directly interacts with the C-terminal activation domain of β
catenin and competes with TCF/LEF factors for β catenin binding
hence repressing its transcriptional activity [10]. Moreover, it forms
a stable tripartite complex with 14-3-3ζ and β catenin hence promot-
ing the β catenin nuclear exclusion and cytoplasmic compartmental-
ization [9]. CBY participation in the constitutive activation of β
catenin in CML was suggested by our recent study showing that a sig-
niﬁcant reduction in CBY expression levels is associated with BCR-ABL
and correlates with nuclear β catenin increment (Mancini et al.,
manuscript in preparation). Further investigation was therefore
addressed towards CBY impact on the β catenin partitioning in
BCR-ABL1+ cells. For this purpose CBY construct was stably
expressed in the BCR-ABL1+ K562 cell line, which exhibits low levels
of CBY transcript and no detectable CBY protein. As expected,
enforced CBY expression promoted prominent relocation of β catenin
to the cytoplasm and transcriptional silencing, resulting in a signiﬁ-
cant reduction of cell growth. Moreover, β catenin cytoplasmatic ac-
cumulation driven by ectopic expression of CBY activated the
ER stress-associated pathway known as UPR. Notably, the CBY-
mediated cytoplasmic accumulation of β catenin leading to UPR acti-
vation intervenes in BCR-ABL1+ cell apoptotic death in response to
IM through events encompassing signal communication to the mito-
chondrial death machinery.
UPR is primarily a survival response which activates a series
of complementary adaptive mechanisms to resolve the protein
misfolding. However, under prolonged and irreversible ER stress con-
ditions it may impair cell viability [11]. UPR activation is initiated by
three transmembrane sensors: the protein kinase RNA-like ER kinase
(PERK), inositol-requiring enzyme 1 (IRE1) and activating transcrip-
tion factor 6 (ATF6). All three proteins are held inactive by interaction
with the ER chaperon binding of immunoglobulin protein (BiP, other-
wise named glucose regulated protein 78 [GRP78] or heat shock pro-
tein [Hsp] A5). Under ER stress conditions they dissociate from BiP
and become activated through autophosphorylation to initiate the
transcriptome reprogramming through the modulation of a vast
number of downstream genes [11]. Activated PERK phosphorylates
the eukaryotic translation initiation factor α-subunit (eIF2α) to re-
press most mRNA translation and protein synthesis [12]. Further-
more, eIF2α phosphorylation promotes selective translation of the
activating translation factor 4 (ATF4) to induce prosurvival genes in-
volved in the control of redox balance, amino acid metabolism and
protein folding [13]. Activated IRE1 splices a 26 nucleotide intron of
the transcription factor X box-binding protein 1 (XBP1) mRNA
which leads to a shift in the mRNA codon reading frame to generate
a new COOH-terminal containing a powerful transactivation domain.
XBP1, in turn, regulates a subset of genes involved in protein folding,
quality control and ER-associated degradation (ERAD) [14]. Activated
ATF6 translocates from the ER to the Golgi where it is cleaved by site 1
and site 2 proteases to generate a p50ATF6 product, whose nuclear
translocation activates ER-stress target genes [15]. A common target
of PERK, IRE1 and ATF6 signaling pathways involved in ER stressmodula-
tion of cell growth and survival is the CCAAT/enhancer-binding protein
(CHOP, also known as growth arrest DNA damage 153 [GADD153])
[16]. Notably, CHOP regulates the expression of BIM, a pro-apoptotic
BH3-only protein whose reduction is critical for resistance of CML hema-
topoietic progenitors to apoptosis [17,18]. Here we provide evidence of
BIM central role in the communication of death signal from ER mem-
branes to the apoptotic machinery following UPR activation by CBY-
driven cytoplasmic accumulation of β catenin.2. Material and methods
2.1. Cells and treatments
A construct containing the whole wt CBY coding sequence was
obtained through ampliﬁcation of cDNA from the HepG2 cell line and
inserted into a commercial plasmid (pcDNA3.1 from Invitrogen)
containing the neomycin phosphotransferase gene which allows the
cell selection in RPMI added with the neomycin analog G418 (see Sup-
plementary section for technical details). The construct coding for a
14-3-3-binding defective protein (CBY S20A) has been previously de-
scribed [9]. Both wt CBY construct and CBY S20A mutant were
transfected in the BCR-ABL1+ cell line K562 by means of electropora-
tion at 0.25 V/960 mF (Equibio Easyject, Optima). Stable CBY expres-
sion in transfected cells was achieved after two month selection in
RPMI 1640 medium (Lonza) added with 10% fetal calf serum (FCS,
Gibco), 1% L-glutamine, antibiotics and with 500 μg/ml G418 in 5%
CO2 and fully humidiﬁed atmosphere at 37 °C. CBY impact on K562
cell growth was investigated by scoring the cell number in liquid cul-
tures and calculating their doubling time using a dedicated software
(GraphPad). Further information about cell growth was obtained from
their potential of originating colonies (aggregates containing > 50
cells) in semisolid culture medium (0.9% methylcellulose), otherwise
named plating efﬁciency (PE). Five micromolar IM was used to inhibit
BCR-ABL TK activity in parental and CBY S20A-transfected K562 cells.
Survival curves carried in methylcellulose media added with IM doses
ranging from 0.05 to 0.5 μMwere used to investigate the drug response
of parental, wt CBY- and CBY S20A-transfected K562. Linear regression
analysis was used to calculate LD50 of each cell type. Five hundred
nanomolar 5-aza-2′-deoxycytidine (5-Aza-CdR) was used to evaluate
the impact of DNA methylation at the CBY promoter on gene expres-
sion. Apoptotic cell deathwasmeasured by the uptake of ﬂuorescinated
Annexin V and propidium iodide (PI, both from Hoffmann-La Roche)
using a FACsCantoII ﬂow cytometer set at 488 nm excitation and
530 nm bandpass ﬁlter wave length for ﬂuorescein detection or
580 nm for PI detection and a dedicated software (DIVA software,
both from Beckton Dickinson).
2.2. RNA analysis
Total RNA was extracted using a commercial kit (SV total RNA iso-
lation system from Promega) according to the manufacturer instruc-
tions. PCR ampliﬁcations were performed with 1.25 U of Taq DNA
Polymerase kit (Roche) in 30 μl of reaction buffer containing 0.4 μM
of each primer, 0.2 mM dNTPs and 5 μl of RT product. PCR was
performed after a 4′ denaturation step at 95 °C, followed by 32 cycles
with a denaturation step at 95 °C for 30″, a primer annealing step at
58 °C (cyclin D1) 59 °C (CBY and beta-2-microglobulin [B2M]) and
60 °C (BIM) for 30″ and an elongation step at 72 °C for 30″. The
following primers were used: 5′-CCGCAATGACCCCGCACGAT-3′ (upper)
and 5′-GCCTGGCGCCCTCAGATGTC-3′ (lower) to amplify cyclin D1
(442 bp), 5′-AGAGTCCTTGCTGGGGGTTCG-3′ (upper) and 5′-CTCC
ACCTCCCGGGTTGATCG-3′ (lower) to amplify the two isoforms (200
and 340 bp) of CBY, 5′-GCCAAGCAACCTTCTGATG-3′ (upper) and 5′-
AATACCCACTGGAGGACCG-3′ (lower) to amplify BIM (286 bp) and
5′-CTCGCGCTACTCTCTCTTTCT-3′ (upper) and 5′-TCACATGGTTCACAC
GGCAGGC-3′ (lower) to amplify B2M (289 bp) as control for RT
efﬁciency.
2.3. Protein analysis
Western blot (WB) and immunoprecipitation (IP)/immunoblotting
analyses were performed on whole cell, nuclear and ER fraction lysates
according to published methods [19]. ER fractions were isolated using
the Mem-PER Eukaryotic Membrane Protein Extraction Reagent
kit (Thermo Scientiﬁc) according to the manufacturer instructions.
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anti-BIM antibodywas purchased fromOncogene. The anti-beta actin an-
tibody used as a control for cytoplasmic protein loading was purchased
from Santa Cruz Biotechnology. The anti-histone H1 used as a control
for nuclear protein loading was purchased from Genetex. The
anti-calnexin antibody used as a control for ER protein loading was pur-
chased from Cell Signaling Technology. All other antibodies were pur-
chased from Cell Signaling Technology. Signal intensities in single blots
obtained in three separate experiments were measured by means of
ChemiDoc-It instrument equipped with dedicated software (Launch
VisionWorksLS from Euroclone). The differences among signal intensities
were evaluated for statistical signiﬁcance using the paired student's t-test.
2.4. Chromatin immunoprecipitation (ChIP)
Cells were ﬁxed in RPMI at 1% ﬁnal concentration of formalde-
hyde. After 10 min incubation at room temperature the reactionK562 K562 WT CBY ORF
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βwas stopped by the addition of 1.25 mM glycine. ChIP was performed
using a commercial kit (EpiQuik Chromatin Immunoprecipitation Kit
from Epigentek) using an anti-5 methylcytosine (5mC) ChIP grade
antibody (ZymoResearch). Fifty nanogram eluted DNA was then am-
pliﬁed by PCR (initial denaturation 95 °C for 10′ m, 35 cycles: dena-
turation: 95 °C for 30″, annealing 58 °C for 30″. and elongation at
72 °C for 30″) using FastStart Taq Polymerase Kit (Roche). The follow-
ing primers were used F-5′ AGGTCAGTGATCCAGCTGCTTGT 3′ and
R-5′ ACTCATGCTGCACACCCGGC 3′ to amplify a 205 bp promoter re-
gion encompassing nucleotides −85 to +120.
2.5. Immunoﬂuorescence (IF) analyses
Cells set on poly-L-lysine-coated glass slides were ﬁxedwith 3% para-
formaldehyde for 10 min at 37 °C, washed with 0,1 M glycine in PBS,
permeabilized in 70% ice-cold ethanol for 2′ at −20 °C and incubated
overnight at 4 °C with primary anti-CBY antibody (0.1% BSA in PBS).
Slideswere then stainedwith secondary anti-rabbit antibody conjugated
with FITC (Santa Cruz Biotechnology) for 2 h at room temperature. β
catenin expression was assessed using a rabbit monoclonal antibody
conjugated with AlexaFluor 647 (Cell Signaling Technology) in PBS
containing 0.1% NP40 and 6-diamidino-2-phenylindole (DAPI in PBS)
was used to stain the nuclear compartment. CHOP expression was
assessed using a mouse monoclonal antibody (Cell Signaling Technolo-
gy). IF microscopic analyses were performed using an Axiovert 40 CFL
by Zeiss, images were acquired with a 100× objective and analyzed
with dedicated software (AxioVision). Ca2+ release was measured in
cells cultured in the presence of 5 μM Indo-1 (Invitrogen) in RPMI at
37 °C for 30′, placed in HBSS buffer containing 1.26 mM CaCl2 and
stainedwith propidium iodide (PI, Sigma) for 30′ on ice, using a ﬂow cy-
tometry instrument (FACSCantoII from BD Biosciences) and a dedicated
software (DIVA from BD Biosciences). IFmicroscopic analysis of Ca2+ re-
lease was performed on Indo-1-treated cells set on poly-L-lysine-coated
glass slides accordingly to the above mentioned procedure. Anti-β tubu-
lin rabbit monoclonal antibody (Alexa Fluor 555 Conjugate, Cell Signal-
ing Technology) was used to stain the cytoplasmic compartment.
3. Results
3.1. Stable expression of CBY drives β catenin cytoplasmatic transloca-
tion and impairs β catenin signaling in BCR-ABL+ cells
Parental K562 cell line exhibits low levels of CBY transcript and no
detectable protein (Fig. 1A and B). Stable transfection of wt CBY con-
struct elicited the expression of CBY transcript (both 240 and 300 bpFig. 1. Stable expression of CBY drives β catenin cytoplasmatic translocation and im-
pairs β catenin signaling in BCR-ABL1+ cells. BCR-ABL1+ cell line K562 was stably
transfected with a wt CBY construct and a mutated CBY S20A construct where a critical
residue (serine 20) within the mode II 14-3-3-binding motif was replaced by alanine
hence preventing the CBY binding with 14-3-3. A—PCR ampliﬁcation showed a mild in-
crease in both CBY transcript isoforms (300 and 240 bp) in wt CBY-transfected cells at
60th day of selection in G418-added medium. B, C—The increment of CBY protein in wt
CBY-transfected cells was more signiﬁcant in the cytoplasmic fraction compared to the
nuclear compartment and paralleled the cytoplasmatic accumulation of β catenin
(p b 0.01). C—Cytoplasmic compartmentalization of CBY and β catenin depends in
CBY's ability to interact with 14-3-3. Accordingly, CBY S20A (which does not bind
14-3-3) was mostly found in the nuclear fraction and β catenin was retained within
the nuclear compartment. D, E—Expression of cyclin D1, a direct β catenin target,
was signiﬁcantly reduced in CBY-expressing K562 cells at both protein (D) and tran-
script (E) levels (p b 0.05 or less). CBY and β catenin expression levels were assayed
by means of WB analysis on both cytoplasmic and nuclear lysates. The interaction of
CBY and 14-3-3σ was assayed by means of IP/immunoblotting using nuclear lysates.
Actin and histone H1 (H1) were used as control of protein loading and to exclude
any cross contamination between the two subcellular compartments (data not
shown). B2M was used as control of PCR ampliﬁcation. Signal intensities in single
blots were quantiﬁed by means of a ChemiDoc-It instrument and dedicated software
(see the Material and methods section for details). The statistical signiﬁcance of differ-
ences in signal intensities was evaluated by means of student's t test. The results illus-
trated here have been conﬁrmed in three separate experiments.
K562 K562 WTCBY ORF
K562
CBY S20A
A PERK
IRE1
BiP
CHOP
ERO1
BIM
Actin
B BIM
B2M
S
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289 bp
286 bp
Fig. 2. CBY-driven cytoplasmatic accumulation of β catenin induces ER stress-associated
UPR in BCR-ABL1+ cells. A—Wt CBY-transfected K562 cells exhibited a signiﬁcant incre-
ment of the UPR sensors PERK and IRE1, likely contingent upon their release from BiP
(whose free isoform was signiﬁcantly raised) as well as of CHOP, BIM (the S and ES
isoforms) and ERO1 (p b 0.05 or less). No increase of the above mentioned protein
bands in K562 transfected with the CBY S20A mutant support the role of β catenin cyto-
plasmic accumulation in the activation of UPR. B—Enhanced transcriptionmediated the in-
crement of BIMexpression inwt CBY-expressingK562 cells. See caption to Fig. 1 for details.
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found in the cytoplasmic compartment (Fig. 1A, B and C). Stable
transfection of CBY S20A mutant construct coding for a 14-3-3-
binding defective protein elicited a similar increment of CBY tran-
scripts (Fig. 1A) [9]. However, its protein was conﬁned within the
nuclear compartment as a consequence of its impaired interaction
with 14-3-3 (Fig. 1B and C). CBY interaction with 14-3-3 scaffolding
proteins in a tripartite complex encompassing β catenin has a central
role in β catenin nuclear-cytoplasmic shuttling [9]. Consistent with
this, the stable expression of wt CBY was associated with a signiﬁcant
increase of β catenin in the cytoplasmic compartment of K562 cells
(p b 0.01), following its binding with 14-3-3 in the nuclear compart-
ment (Fig. 1B and C). These ﬁndings conﬁrmed results achieved in
other cell types [20]. As expected, CBY S20A impaired interaction with
14-3-3 was associated with nuclear retention of β catenin, further
supporting the participation of the CBY/14-3-3 complex in β catenin cy-
toplasmic relocation (Fig. 1B and C). Cytoplasmic relocation of CBY and
β catenin in K562 cells overexpressing the wt CBY construct was con-
ﬁrmed by IF analyses (Supplementary section, Fig. 2S).
β catenin nuclear exclusion precludes its transcriptional activity.
Accordingly, the expression of cyclin D1, a direct target of the β
catenin/TCF complex critical for deregulated proliferation of BCR-
ABL-transformed cells, was signiﬁcantly reduced (p b 0.01) in wt
CBY-expressing K562, through events proceeding from reduced tran-
scription (Fig. 1D and E) [21]. In contrast, the expression of cyclin D1
transcript and protein did not exhibit signiﬁcant differences in CBY
S20A-transfected cells compared to parental cells (Fig. 1D and E).Impaired β catenin signaling and decreased cyclin D1 expression con-
curred to reduce the proliferation rate of wt CBY-overexpressing
K562 cells, whose doubling time was extended from 48 to 88 h
(p b 0.001), while the CBYS20A mutant showed no overt effects on
K562 proliferation (p b 0.1) (Supplementary section, Fig. 3S). From
these results we conclude that enforced CBY expression revokes β
catenin signaling in BCR-ABL1+ cells through events encompassing
its ability of binding and relocating β catenin to the cytoplasm.
3.2. CBY-driven cytoplasmatic accumulation of β catenin induces ER
stress-associated UPR in BCR-ABL+ cells
A previous study showed that β catenin accumulation inhibits
cancer cell growth by activating the ER stress-associated UPR [22].
In agreement with this, β catenin cytoplasmic accumulation driven
by enforced CBY expression in K562 cells was associated with signif-
icant increments of PERK and IRE1 (p b 0.001), most likely contingent
upon their release from the ER chaperon BiP, CHOP and BIM (p b 0.05
or less) (Fig. 2A). CHOP induction associated with wt CBY enforced
expression in K562 cells was conﬁrmed by IF analyses (Supplementa-
ry section, Fig. 4S). Post-transcriptional and transcriptional mechanisms,
including BIM phosphorylation (which promotes ubiquitination and
proteasomal degradation) and direct transcriptional induction by CHOP,
have been involved in BIM activation by ER stress [23]. Here we provided
evidence of enhanced BIM transcription in K562 cells overexpressing wt
CBY (p b 0.01), most likely contingent upon CHOP induction (Fig. 2B).
The signiﬁcant increase of ER oxireductin 1 (ERO1) (p b 0.01), the prima-
ry electron acceptor for disulﬁde bond formation and a potential source of
oxidative stress, provide a further proof of CHOP activation in wt
CBY-transfected K562 cells (Fig. 2A) [24]. Notably, CHOP has been impli-
cated in the inhibition of β catenin/TCF-dependent transcriptional activa-
tion through binding to TCF and interfering with TCF association with
DNA [25,26]. CHOP induction may therefore contribute to reduce cyclin
D1 transcription associated with the enforced wt CBY expression (Fig.
1D and E). There were no major differences in levels of aforementioned
proteins in K562 cells transfected with the CBY S20A mutant compared
to parental cell line, supporting the central role of CBY/14-3-3 interaction
in theUPR activation associatedwith theβ catenin cytoplasmic relocation
(Fig. 2A and B). These results let conclude that the cytoplasmic accumula-
tion of β catenin promoted by enforced CBY expression activates the ER
stress-associated UPR in BCR-ABL1+ cells.
3.3. CBY is a component of β catenin cytoplasmatic relocation promoting
ER stress-associated UPR in response to IM in BCR-ABL1+ cells
Nuclear import of β catenin in BCR-ABL1+ cells depends on
BCR-ABL-induced phosphorylation at tyrosine residues Y86 and
Y654. Accordingly, BCR-ABL dephosphorylation in response to IM in-
duces β catenin dephosphorylation hence promoting its rapid cyto-
plasmic relocation [7]. Here we conﬁrmed the signiﬁcant early
increment of cytoplasmic β catenin in the parental K562 cell line
within 1st and 5th h of IM treatment, paralleling BCR-ABL dephos-
phorylation at Tyr245 in the SH2-linker region (p b 0.01 or less) and
followed by its reduction at 24th h (p b 0.01), most likely contingent
upon degradation by the APC/Axin/GSK3β destruction complex
(Fig. 3A) [7]. Moreover, we found a signiﬁcant and persistent incre-
ment of CBY protein in the cytoplasmic compartment of K562 cells
since 1st up to 24th h of IM treatment (p b 0.001 or less) (Fig. 3A).
Steady cytoplasmic levels of CBY in K562 cells expressing the CBY
S20A mutant treated with IM suggest that the binding with 14-3-3
has a critical role in CBY subcellular location (data not shown). The
observed increase in CBY protein levels in response to IM resulted,
at least partly, from elevated gene transcription. Both 340 and
200 bp isoforms of the CBY transcript were, in fact, signiﬁcantly
raised since the 1st up to the 5th h of IM treatment (p b 0.001 or
less) (Fig. 3B). Further investigation was addressed to depict the
5-Aza-CdR - 24h 48h
D ChIP 5mc-CBY promoter
INPUT DNA
E CBY
B2M
F CBY
catenin
Actin
B CBY
B2M
h42h5h3h1-MI
A PBcr-Abl (Y245)
catenin
Cby
Actin
340 bp
200 bp
289 bp
C ChIP 5mC-CBY promoter
INPUT DNA
340 bp
200 bp
289 bp
β
β
Fig. 3. CBY is a component of β catenin cytoplasmatic relocation in response to IM in BCR-ABL1+ cells. A—BCR-ABL protein dephosphorylation at tyrosine (Y) 245 in response to IM
(5 μM) was associated with a signiﬁcant increment of cytoplasmic CBY and β catenin up to the 5th h (p b 0.01 or less). CBY protein expression was still signiﬁcantly higher com-
pared to untreated controls at the 24th h of IM treatment (p b 0.001). By the time, the β catenin expression underwent a signiﬁcant reduction (p b 0.01) likely contingent upon
degradation by the APC/Axin/GSK3β destruction complex. B—Both CBY transcripts (340 and 200 bp) were signiﬁcantly elevated up to the 5th h of IM treatment (p b 0.001) and
returned to near basal levels at the 24th. C—The increase of CBY transcript in response to IM was associated with a signiﬁcant reduction of 5mC content at a CBY promoter region
encompassing nucleotides−85 to +120 (p b 0.05) since 1st up to the 24th h of exposure to the drug. D, E, F—The gene promoter de-methylation in response to 5-Aza-CdR elicited
a signiﬁcant increment of CBY transcripts and protein, associated with cytoplasmic relocation of β catenin whose GSK3β-induced degradation was precluded by persistent BCR-ABL
TK (data not shown). PCR ampliﬁcation of ChIP products obtained with an anti-5mC antibody was used to evaluate the amount of 5mC at the CBY promoter. The input DNA was
used as control for PCR reaction. See caption to Fig. 1 for further technical details.
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sponse to IM. PCR ampliﬁcation of ChIP products obtained with an
anti-5mC ChIP grade antibody revealed a signiﬁcant reduction of
5mC at a 205 bp sequence of CBY promoter encompassing nucleo-
tides −85 to +120 since the 1st up to the 24th h of IM treatment
(p b 0.05 or less) (Fig. 3C). Further experiments carried in K562 cell
line treated with the de-methylating agent 5-Aza-CdR conﬁrmed
that gene promoter methylation is a critical regulatory component
of CBY expression. The signiﬁcant reduction of 5mC content at the
aforesaid region of CBY promoter elicited by 5-Aza-CdR (500 nM)
was, in fact, associated with the increment of CBY transcripts and pro-
tein (p b 0.05 or less) (Fig. 3D, E and F). As in response to IM, the sig-
niﬁcant increase of CBY protein paralleled β catenin cytoplasmic
accumulation. However, in consequence of persistent BCR-ABL phos-
phorylation, β catenin was not addressed towards the APC/Axin/
GSK3β-dependent destruction up to the 48th h of exposure to
5-Aza-CdR (p b 0.001) (Fig. 3F and data not shown). Notably, paren-
tal, wt CBY- and CBY S20A-transfected K562 cells did not exhibit sig-
niﬁcant differences in their response to IM, with LD50 ranging from
0.048 to 0.057 μM (p b 0.1), suggesting that CBY is not a critical com-
ponent of BCR-ABL1+ cell response to IM (Supplementary section,
Fig. 5S).
The β catenin cytoplasmic accumulation in response to IM was as-
sociated with the induction of ER stress-associated UPR signals, in-
cluding PERK, CHOP and BIM (p b 0.05 or less) (Fig. 4A). CHOP
induction in response to IM was conﬁrmed by IF analyses (Fig. 4B).
As expected, BIM increment was directed by enhanced transcription
since the 1st up to the 24th h of IM treatment (p b 0.05 or less)
(Fig. 4C). Interestingly, PERK, CHOP and BIM expressions were also
raised in response to 5-Aza-CdR, further supporting the role of
CBY-driven cytoplasmic accumulation of β catenin in UPR activation
(p b 0.05 or less) (Fig. 4D). A previous study demonstrated that BIM
participates in the death signal transmission from ER to mitochondria
and contributes to the execution phase of apoptosis through multiple
events culminating in the activation of ER resident caspase 12 [27].
Accordingly, the chain of events proceeding from BIM induction in re-
sponse to IM culminated in BIM translocation to ER membranes andactivation of ER-resident caspase 12, whose levels were signiﬁcantly
increased at the 24th h of IM treatment both at the ER membranes
and in the cytoplasms of K562 cells (p b 0.01 or less) (Fig. 4E).
Thereafter, the mobilization of ER Ca2+ stores initiates the activation
of cytoplasmic death pathways and sensitizes mitochondria to
proapoptotic signals. A massive Ca2+ release of from cellular stores
into the cytosol in parental K562 cells at the 24th h of IM treatment
was detected by Indo-1 uptake and conﬁrmed by cytoﬂuorimetric
analysis (Fig. 5A and B). No signiﬁcant changes in Ca2+ within the
stores were apparent in CBY S20A-transfected K562 cells, where β
catenin nuclear export was precluded by CBY mutation at the critical
residue for interaction with 14-3-3 (Fig. 5) [28]. These data support
the notion that CBY induction proceeding from epigenetic modiﬁca-
tions has a role in β catenin cytoplasmic accumulation which acti-
vates the ER-associated UPR in response to IM in BCR-ABL1+ cells.
Notably, enforced CBY expression alone neither elicited caspase 12
activation nor addressed K562 cells towards apoptotic death, further
supporting that apoptotic cell death in response to IM is triggered
by complementary signals evoked by BCR-ABL TK inhibition (Supple-
mentary section, Fig. 6S).
4. Discussion
β catenin is a central component of BCR-ABL leukemogenesis due to
its role in the LSC self-renewal [4–6]. Its signaling in CML cells is contin-
gent upon stabilization by BCR-ABL phosphorylation at critical tyrosine
residues for protein interaction with the APC/Axin/GSK3 destruction
complex and in-frame splice inactivating deletions of the GSK3 kinase
domain [7,8]. In all instance, the prerequisite of β catenin transcription-
al activation is its nuclear import. Multiple mechanisms are involved in
the β catenin shuttling between nuclear and cytoplasmatic compart-
ments. They encompass β catenin post-transcriptional modiﬁcations
(phosphorylation, acetylation and glycosylation) and β catenin trans-
porters promoting either the protein nuclear import (BMP and actin
membrane-bound inhibitor [BAMBI] pseudoreceptor, Forkhead box
M1 [FOXM1], p21-activated protein kinase 4 [PAK4]) or export (APC,
Menin 1 [MEN1], Ran binding protein 3 [RanBP3], c-Jun N-terminal
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Fig. 4. UPR activation in response to IM promotes BIM translocation at ER membranes and activation of the ER resident caspase 12. A—PERK, CHOP and BIM expressions were sig-
niﬁcantly raised at 24 h of IM treatment (p b 0.05 or less). B—IF microscopy conﬁrmed CHOP induction in response to IM. CHOP staining (red) was absent in untreated K562 cells
but intense in the cytoplasmic compartment after 24 h exposure to IM, as shown by the double staining with anti-CHOP antibody and DAPI, which labels the nuclear compartment.
C—BIM increment was attributable to enhanced transcription (p b 0.05). D—CBY-driven cytoplasmic relocation of β catenin in response to 5-Aza-CdR resulted in a signiﬁcant in-
crease of PERK, CHOP and BIM. E—BIM increment at 24th of IM treatment was associated with its translocation at ER membranes (the only ES isoform) and increase of
ER-resident caspase 12 in its cleaved isoform (36 kDa) both at the ER membranes and in the cytoplasm. Calnexin was used as a control for loading of proteins extracted from
ER membranes. IF microscopic analyses were performed using an Axiovert 40 CFL by Zeiss. See caption to Fig. 1 for further details.
1825M. Mancini et al. / Cellular Signalling 25 (2013) 1820–1827kinase [JNK], leucine zipper tumor suppressor 2 [LZTS2]) in most in-
stances cell type speciﬁc [29–39]. Still, the role of β catenin transporters
in β catenin nuclear translocation associatedwith BCR-ABL is unknown.
CBY antagonistic effect onβ catenin signaling proceeds from its bind-
ing with the β catenin C-terminal activation domain required for β
catenin interaction with TCF/LEF factors and with 14-3-3 scaffolding
proteins ζ and σ in a stable tripartite complex encompassing β catenin
and promoting its nuclear export [9,10]. Our recent work showing a
signiﬁcant CBY reduction paralleling nuclear β catenin increases in
BCR-ABL1+ hematopoietic progenitors suggested that CBY may have
a role in the β catenin signaling in CML (Mancini et al., manuscript in
preparation). Here we showed that CBY enforced expression in K562
cell line (which exhibits low levels of Cby transcript and noprotein) pro-
motes β catenin cytoplasmic relocation and revokes the transcriptional
induction of β catenin target genes, including cyclin D1 (Fig. 1, Supple-
mentary section Fig. 2S) [21]. The activation of ER stress-associatedUPR proceeding from the enhanced expression of UPR sensors PERK
and IRE1α, and CHOP is a component of growth arrest associated with
the CBY-driven β catenin cytoplasmic accumulation in BCR-ABL1+
cells (Fig. 2A). CHOP is a bZiP transcription factor implicated in BIM tran-
scriptional induction in response to ER stress [16,23]. Accordingly, its in-
crement in wt CBY-transfected K562 cells was associated with a
signiﬁcant increase of BIM transcription (Fig. 2B).Moreover, it may inte-
grate TCF-dependent cyclin D1 reduction (Fig. 1E) [25,26]. Cyclin D1 and
BIM play central roles in the BCR-ABL phenotype suggesting that
changes in their expression may contribute to the growth arrest of
K562 overexpressing wt CBY construct (Supplementary section, Fig.
3S) [17,18,21].
Moreover, we demonstrated that the UPR activation promoted by
CBY-driven cytoplasmatic accumulation of β catenin is a component of
BCR-ABL1+ cell response to IM (Figs. 3A, 4A, B and C). CBY induction
in response to IM was, at least partly, contingent upon transcriptional
A
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Fig. 5. Release of ER Ca2+ stores is the last step of K562 cell commitment to death in response to IM. A—Indo-1 incorporation (green) by K562 cells was signiﬁcantly raised at the 24th h of
IM treatment. Its release into cytoplasm was conﬁrmed by its colocalization with β tubulin (color red) used as marker of the cytoplasmic compartment. B—Cytoﬂuorimetric analysis of
Indo-1 ﬂuorescence conﬁrmed the enhanced Ca2+ release following IM treatment. IFmicroscopic analyseswere performed using an Axiovert 40 CFL by Zeiss. Ca2+ releasewasmeasured
using a ﬂow cytometry instrument (FACSCantoII from BD Biosciences) and a dedicated software (DIVA from BD Biosciences). See the Material and methods section for technical
details.
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sequence of CBY promoter encompassing nucleotides −85 to +120
supports that CBY transcriptional induction is driven by the promoter
de-methylation associated with the inhibition of BCR-ABL TK (Fig. 3C).
Indeed, the signiﬁcant increment of CBY transcription in response to
5-Aza-CdR further supports the epigenetic regulation of the expression
of critical genes for BCR-ABL leukemic phenotype such as BIM,whose re-
duced expression has been ascribed to the promoter hypermethylation
associated with BCR-ABL TK (Fig. 3D, E and F) [40].
CBY increment in response to IM was an early event occurring
within the 5th h from BCR-ABL TK inhibition by IM and persisting up
to the 24th h, when cytoplasmatic β catenin was reduced below the
levels of untreated cells, most likely in consequence of the GSK3β-
induced degradation (Fig. 3A) [7]. CBY effect onβ catenin subcellular re-
location arises from its binding with β catenin in a tripartite complex
encompassing 14-3-3 scaffolding proteins and tethered by AKT phos-
phorylation of CBY at a critical residue (serine 20) within the mode II
14-3-3-binding motif [9]. Accordingly, in K562 cells expressing the
CBY S20A mutant, where serine 20 (whose phosphorylation by AKT is
necessary for 14-3-3 binding) was replaced by an alanine residue, CBY
binding with 14-3-3 and β catenin cytoplasmatic translocation were
both precluded either in untreated or after 24 h of IM treatment
(Fig. 1B and data not shown). As a matter of fact, the AKT persistent
phosphorylation in BCR-ABL1+ cells where the fusion protein enzy-
matic activity is inhibited by TK inhibitors may be the central compo-
nent of CBY/β catenin/14-3-3 complex assembly [41,42]. Still, theactivation of UPR by CBY-driven cytoplasmatic accumulation of β
catenin is not the central component of BCR-ABL1+ cell response to
IM, which is rather driven by complementary signals evoked by
BCR-ABL TK inhibition (Supplementary section, Fig. 5S). In particular,
further investigation is required to elucidate the putative synergism of
CHOP and FOXO3a in BIM transcriptional induction in BCR-ABL1+
cell response to IMand/or the role of BIM post-transcriptionalmodiﬁca-
tions affecting its stability in the death signal transmission from ER to
mitochondria [23,43].
A previous study showed that the ER stress-associated UPR
evoked by β catenin cytoplasmic accumulation in multiple myeloma
cells is promoted by the inhibition of protein kinase C (PKC), which pre-
vents the β catenin phosphorylation necessary for proteasomal degra-
dation, blocks cell proliferation through CHOP-dependent induction of
p21(WAF1) and triggers apoptosis through c-Jun-dependent induction
of p73 [22]. The PKCι isoform is a BCR-ABL target downstream of the
RAS/MEK/ERK axis [44]. PKCι inhibition in response to IMmay therefore
represent a complementary route to the β catenin cytoplasmic reloca-
tion in our BCR-ABL1+ model.
The last mention deserves the pathologically misfolded nature of
BCR-ABL protein, which is censored by BCL2-associated athanogene 1
(Bag1), ubiquitinated by the C-terminus of constitutive heat shock cog-
nate 70-interacting protein (CHIP) and addressed towards proteasomal
degradation [45]. A previous study showed that the BCR-ABL-induced
activation of UPR has a prosurvival impact encompassing the transcrip-
tional induction of genes required to restore ER homeostasis [46]. More
1827M. Mancini et al. / Cellular Signalling 25 (2013) 1820–1827recently, the ER stress associatedwith BCR-ABL has been ascribed to the
upregulation of PERK-eIF2α pathway and the cell death induction by IM
to the suppression of PERK-eIF2α phopshorylation [47]. Further studies
are required to reconcile such conﬂicting results. In particular, the
BCR-ABL impact on the amplitude and kinetics of UPR signaling, differ-
ent regulation of UPR sensors and participation of IRE downstream sig-
nals proceeding from JNK activation in ER stress-induced apoptosis
following BCR-ABL TK inhibition by IM must be investigated [48–50].
5. Conclusions
Here we showed that CBY plays a role in β catenin signaling in
CML. Binding of CBY with β catenin in a stable ternary complex
encompassing 14-3-3 facilitates β catenin nuclear export thereby
suppressing its transcriptional activity and BCR-ABL1+ cell growth.
The activation of ER stress-associated UPR proceeding from
CBY-driven β catenin cytoplasmatic accumulation is a further compo-
nent of BCR-ABL1+ cell growth reduction. Notably, UPR activation by
CBY-driven β catenin cytoplasmic accumulation also intervenes in the
BCR-ABL1+ cell response to IM. In this context, CBY induction is driv-
en by epigenetic events encompassing the promoter de-methylation
and is crucial for β catenin cytoplasmic relocation. The proapoptotic
BH3-only protein BIM has a central role in the death signal transmis-
sion from ER to mitochondria hence contributing to the apoptosis ex-
ecution phase through multiple events culminating in the activation
of ER resident caspase 12 and mobilization of ER Ca2+ stores.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.cellsig.2013.05.019.
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